Clinical trials: Gene Mutations
Duodenal Diseases
Endoscopic Characteristics of Duodenal and Ampullary Lesions
The purpose is to investigate whether polyps that look different at endoscopy, have formed via different mutations and have different risks of turning into cancer.
- Trial name
- DUO/AMP-LST (NCT01556399)
- Testing
- Tissue Sampling
- Where
- Australia
- Volunteers
- 350 people
- Sponsor
- Professor Michael Bourke
Pancreatic Cancer
An Open-label, Multicenter, Phase II Clinical Study to Evaluate HRS-7058 in Patients With Pancreatic Cancer
This is a multicenter, open-label, single-arm, phase II cilinical trial designed to evaluate the efficacy and safety of the KRAS G12C selective inhibitor HRS-7058 in patients with KRAS G12C-mutated advanced pancreatic cancer who…
- Trial name
- NCT07589569
- Testing
- HRS-7058
- Where
- 2 sites in China
- Volunteers
- 92 people
- Sponsor
- Shandong Suncadia Medicine Co., Ltd.
Lynch Syndrome, Lynch Syndrome I
Lynch Syndrome X-Talk of Enteral Mucosa With Immune System
Lynch syndrome (OMIM #120435) is the most common dominantly inherited colorectal cancer syndrome with an estimated prevalence of 1:270 individuals.
- Conditions
- Lynch Syndrome, Lynch Syndrome I, Lynch Syndrome II, Lynch Syndrome I (Site-specific Colonic Cancer)
- Trial name
- LYNX-EYE (NCT06708429)
- Testing
- LYNX EYE (Lynch syndrome X-Talk of Enteral mucosa with Immune System)
- Where
- 5 sites in United States, Italy
- Volunteers
- 300 people
- Sponsor
- San Raffaele University
Breast Cancer Risk, Ovarian Cancer Risk
Population Based Germline Testing for Early Detection and Prevention of Cancer
PROTECT-C is a research study offering genetic testing to people to see whether they have a genetic change that increases their risk of breast, ovary, bowel, and/or womb cancer.
- Conditions
- Breast Cancer Risk, Ovarian Cancer Risk, Cancer Gene Mutation
- Trial name
- PROTECT-C (NCT07498829)
- Testing
- Genetic testing for Cancer Susceptibility Genes (CSGs) (BRCA1, BRCA2, RAD51C, RAD51D, BRIP1, PALB2, MLH1, MSH2, MSH6) and personalised breast and ovarian cancer risk
- Where
- United Kingdom
- Volunteers
- 6,000 people, healthy volunteers welcome
- Sponsor
- Queen Mary University of London
Pancreatic Cancer, Pancreatic Adenocarcinoma
Germline Mutations Associated With Hereditary Pancreatic Cancer in Unselected Patients With Pancreatic Cancer in Mexico
Pancreatic cancer is a highly lethal disease. The cause of pancreatic cancer is multifactorial. However, around 10% of cases are associated with hereditary predisposition.
- Trial name
- NCT05305001
- Testing
- Invitae Multi-Cancer Panel ®
- Where
- Mexico
- Volunteers
- 107 people
- Sponsor
- Instituto Nacional de Ciencias Medicas y Nutricion Salvador Zubiran
Breast Cancer
A Phase I, Open-Label, 2 Part Multicentre Study to Assess the Safety and Efficacy of Olaparib in Combination With Carboplatin in Patients With Advanced HER-2 Negative Breast Cancer
This is an open-label study to assess the safety, tolerability and efficacy of olaparib in combination with carboplatin. There are two parts in this study: Part A, a dose escalation in patients with advanced Human Epidermal…
- Trial name
- NCT02561832
- Testing
- Olaparib, Carboplatin, Anthracycline
- Where
- 7 sites in United States, Spain
- Volunteers
- 15 people
- Sponsor
- AstraZeneca
Non Small Cell Lung Cancer
Study of Osimertinib+Bevacizumab+Chemotherapy for EGFR+ Advanced Non-Small Cell Lung Cancer With Concurrent Mutations
This is a single-center, open-label, phase I clinical trial aimed to evaluate the efficacy and safety of Osimertinib+Bevacizumab+Carboplatin and Pemetrexed for Untreated Patients With EGFR Mutation Advanced Non-squamous Non-Small…
- Trial name
- NCT05507606
- Testing
- Osimertinib, Bevacizumab Biosimilar IBI305, Carboplatin
- Where
- China
- Volunteers
- 50 people
- Sponsor
- Tianjin Medical University Cancer Institute and Hospital
Non-small Cell Lung Cancer
Non-interventional, Prospective Study to Determine Prevalence of EGFR Mutations in Non-small Cell Lung Cancer
This prospective, multicountry, multicentre, non-interventional study plans to include patients who have undergone surgery for early-stage (IA to IIIB on the basis of pathologic criteria) non-squamous NSCLC up to 6 weeks prior to…
- Trial name
- EARLY-EGFR (NCT04742192)
- Where
- 33 sites in Argentina, Chile and 13 more
- Volunteers
- 601 people
- Sponsor
- AstraZeneca
Metastatic Colorectal Cancer, KRAS Gene Mutation
Expanded Access of Onvansertib With FOLFIRI and Bevacizumab for the Second-Line Treatment of Participants With KRAS-Mutated Metastatic Colorectal Cancer
This is an expanded access program for eligible participants designed to provide access to onvansertib in combination with FOLFIRI and bevacizumab.
- Trial name
- NCT04446793
- Testing
- Onvansertib, Bevacizumab, FOLFIRI
- Sponsor
- Cardiff Oncology
NSCLC
Afatinib in NSCLC With HER2 Mutation
The purpose of this study is to investigate the control of disease in pretreated patients with advanced non small cell lung cancer (NSCLC) harbouring HER2 exon 20 mutations as well as the safety and tolerability (how severe the…
- Trial name
- NICHE (NCT02369484)
- Testing
- Afatinib
- Where
- 5 sites in Germany, Netherlands and 2 more
- Volunteers
- 13 people
- Sponsor
- ETOP IBCSG Partners Foundation
Neutropenia
AMD 3100 for Treatment of Myelokathexis
This is an initial study to determine if CXCR4 inhibitor AMD 3100 or plerixafor may be a potential treatment for neutropenia due to CXCR4 mutations, the myelokathexis or WHIM (warts, hypogammaglobulinemia, immunodeficiency and…
- Trial name
- NCT01058993
- Testing
- AMD3100 or plerixafor
- Where
- United States
- Volunteers
- 6 people
- Sponsor
- University of Washington
Colorectal Cancer
Everolimus in Treating Patients With Advanced or Metastatic Colorectal Cancer That Did Not Respond to Previous Therapy
RATIONALE: Everolimus may stop the growth of tumor cells by blocking some of the enzymes needed for cell growth and by blocking blood flow to the tumor.
- Trial name
- NCT00390364
- Testing
- everolimus, antiangiogenesis therapy, biopsy
- Where
- United States
- Volunteers
- 1 people
- Sponsor
- Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins
Li-Fraumeni Syndrome, Hereditary Cancer Syndromes
Biomarker Monitoring in TP53 Mutation Carriers
Purpose This study is an 'N-of-one' observational study focusing on individuals with a hereditary predisposition to cancer due to a genetic mutation in the TP53 gene.
- Conditions
- Li-Fraumeni Syndrome, Hereditary Cancer Syndromes, TP53 Gene Germline Mutation Carrier
- Trial name
- NCT02289326
- Where
- United States
- Volunteers
- 6 people, healthy volunteers welcome
- Sponsor
- Scripps Health
Breast Cancer
Studying Tissue Samples From Women With Breast Cancer Who Were Treated on Clinical Trial NCCTG-N9831
This research study is looking at tissue samples from women with breast cancer who were treated on clinical trial NCCTG-N9831. Studying samples of tissue from patients with cancer in the laboratory may help doctors learn more…
- Trial name
- NCT00898898
- Testing
- diagnostic laboratory biomarker analysis
- Volunteers
- 2,837 people
- Sponsor
- Alliance for Clinical Trials in Oncology
Lung Cancer
Mutation Detection of EBUS-TBNA Specimens Using NGS
The objective of the study was to compare the value of routine gene testing and next-generation sequencing (NGS) in detecting gene mutations of small specimens obtained by endobronchial ultrasound transbronchial needle aspiration…
- Trial name
- NCT02420405
- Testing
- Routine gene testing, Next-generation sequencing
- Where
- China
- Volunteers
- 78 people
- Sponsor
- Jiayuan Sun
Advanced Solid Tumors Harboring RAS Mutations or Amplifications
A Phase I Study of HRS-7172 in Participants With Advanced Solid Tumors Harboring RAS Mutations or Amplifications
This is a phase I study of HRS-7172 to evaluate safety, tolerability and pharmacokinetics in participants with advanced solid tumors harboring RAS mutations or amplifications.
- Trial name
- NCT07142980
- Testing
- HRS-7172 Tablets
- Where
- China
- Volunteers
- 120 people
- Sponsor
- Jiangsu HengRui Medicine Co., Ltd.
HIV Infection
Evaluation of Genetic Markers as Explanations for the Observed Differences in Disease Progression in HIV+ Youth
This protocol is a study of HIV+ young people who were identified as having certain HIV-1 specific T-cell responses and genetic markers while previously enrolled in the 5-year longitudinal adolescent study, "REACH." Blood samples…
- Trial name
- NCT00107029
- Where
- 10 sites in United States
- Volunteers
- 113 people
- Sponsor
- University of North Carolina, Chapel Hill
HER2-ve Metastatic Breast Cancer, Germline BRCA1/2 Mutations
To Study Clinical Effectiveness and Safety of Olaparib Monotherapy in Metastatic Breast Cancer Patients.
This open-label, multi-centre phase IIIb study will assess the effectiveness, benefits and potential harms in the use of olaparib monotherapy treatment for patients with HER2-ve metastatic breast cancer associated with germline…
- Conditions
- HER2-ve Metastatic Breast Cancer, Germline BRCA1/2 Mutations, Somatic BRCA1/2 Mutations
- Trial name
- NCT03286842
- Testing
- Olaparib
- Where
- 123 sites in United States, Bulgaria and 13 more
- Volunteers
- 256 people
- Sponsor
- AstraZeneca
Breast Cancer
PARP Inhibition for Triple Negative Breast Cancer (ER-/PR-/HER2-)With BRCA1/2 Mutations
The purpose of this trial is to evaluate 2-year disease-free survival in this patient population treated with single agent cisplatin and patients treated with cisplatin in combination with Rucaparib following preoperative…
- Trial name
- NCT01074970
- Testing
- Cisplatin, Rucaparib
- Where
- 27 sites in United States
- Volunteers
- 135 people
- Sponsor
- Hoosier Cancer Research Network
Pulmonary Arterial Hypertension
Effect of BMPR-2 Gene Mutations on Hemodynamic Response by Iloprost Inhalation in Pulmonary Arterial Hypertension
In the present study, the investigators want to investigate the prevalence of BMPR-2 gene mutations in the Korean PAH patients (Step-I) and to test that the PAH patients treated with iloprost inhalation solution (Ventavis®) would…
- Trial name
- PILGRIM (NCT01054105)
- Testing
- Iloprost
- Where
- 6 sites in South Korea
- Volunteers
- 73 people
- Sponsor
- Gachon University Gil Medical Center
The first 1,020 results can be paged through. Add a filter or change the sort order to reach the rest.